Trusted Resource for Clinical Trials, Protocols & Progress
As centralized monitoring becomes a regulatory norm, sponsors are under increased pressure to not only identify data issues through Source Data Review (SDR), but also to act on those findings via Corrective and Preventive Actions (CAPA) and deviation response workflows. Without this linkage, SDR can appear passive—undermining its value in risk-based monitoring and inspection defense.
Click to read the full article.
Remote Source Data Review (SDR) has become a key strategy for maintaining clinical trial oversight in decentralized and hybrid models. While effective, it introduces new regulatory expectations—particularly around documentation, reviewer accountability, and traceability of oversight actions. Consequently, auditors from regulatory agencies such as the FDA, EMA, and MHRA are placing increasing scrutiny on centralized monitoring activities during Good Clinical Practice (GCP) inspections.
Click to read the full article.
Remote Source Data Review (SDR) has become a vital component of centralized monitoring in modern clinical trials. It supports real-time oversight, risk-based quality management, and subject safety assurance. However, its growing use has led to heightened regulatory scrutiny from agencies like the FDA, EMA, and MHRA.
Click to read the full article.
Source Data Review (SDR) is a cornerstone of centralized monitoring in decentralized clinical trials. While technology enables remote access to subject-level data, the success of SDR depends on structured oversight and measurable performance. Regulatory agencies such as the FDA and EMA expect sponsors to not only perform SDR but also monitor its quality using meaningful metrics. These indicators ensure that reviewers are effective, findings are acted upon, and the entire process remains compliant with GCP principles.
Click to read the full article.
The evolution of decentralized clinical trials and remote monitoring practices has brought virtual site visits to the forefront of regulatory oversight strategies. Both sponsors and clinical sites must now demonstrate compliance with Good Clinical Practice (GCP) while conducting remote visits that meet the expectations of authorities like the FDA, EMA, and ICH.
Click to read the full article.
Remote monitoring has become a foundational element of modern clinical trial oversight, particularly under risk-based monitoring (RBM) models. Regulatory agencies like the FDA, EMA, and ICH have endorsed risk-based approaches that emphasize critical data and processes, especially during remote and virtual site visits. One essential component of ensuring compliance and operational readiness in remote oversight is the use of a structured Pre-Visit Checklist.
Click to read the full article.
The shift from traditional on-site monitoring to virtual and hybrid site visits has become a strategic necessity in clinical trials. Sponsors, CROs, and regulatory agencies have embraced these models to ensure business continuity during disruptions like pandemics, but also to reduce cost and increase flexibility. However, this shift brings complexity in oversight models and operational documentation—especially Standard Operating Procedures (SOPs) and CAPA implementation.
Click to read the full article.
As virtual site visits become a mainstay in clinical trial oversight, proper documentation is crucial for inspection readiness. Regulatory agencies like the FDA, EMA, and ICH require that remote monitoring visits be supported with detailed, audit-ready reports—just like traditional on-site visits. However, virtual visit reports have their own set of expectations, including technology logs, access validations, and e-signature tracking.
Click to read the full article.
As clinical trials increasingly adopt decentralized and remote models, virtual site visits have become central to trial oversight. However, poorly planned technology infrastructure can lead to regulatory violations, data breaches, and failed inspections. The FDA, EMA, and ICH all expect sponsors to validate, document, and secure virtual visit tools in alignment with GCP and Part 11 requirements.
Click to read the full article.
As clinical trials increasingly adopt decentralized and remote models, virtual site visits have become central to trial oversight. However, poorly planned technology infrastructure can lead to regulatory violations, data breaches, and failed inspections. The FDA, EMA, and ICH all expect sponsors to validate, document, and secure virtual visit tools in alignment with GCP and Part 11 requirements.
Click to read the full article.
